New drug combo shows promise for tough-to-treat lymphoma
NCT ID NCT04067037
First seen Feb 01, 2026 · Last updated Jun 13, 2026 · Updated 18 times
Summary
This study tests whether adding the drug camrelizumab to standard chemotherapy (AVD) helps people with advanced classical Hodgkin lymphoma who have not been treated before. About 60 adults aged 18 to 75 will receive the combination. The main goal is to see how many patients have their cancer completely disappear after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
An Yang Tumor Hospital
Anyang, Henan, 455000, China
-
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
Zhengzhou, Henan, China
-
The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology
Luoyang, Henan, 471003, China
Conditions
Explore the condition pages connected to this study.